HCW BiologicsHCWB
Market Cap: $21.6M
About: HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
Employees: 45
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
0.15% more ownership
Funds ownership: 3.06% [Q1] → 3.21% (+0.15%) [Q2]
5% less funds holding
Funds holding: 20 [Q1] → 19 (-1) [Q2]
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
59% less capital invested
Capital invested by funds: $1.9M [Q1] → $784K (-$1.11M) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for HCWB.